Gilberto Lopes

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

Planning cancer control in Latin America and the Caribbean

Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević et al. · The Lancet Oncology · 2013 · 496 citations · Full text

Preventive Medicine, Medicine, Global Health +7

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim et al. · The Lancet Oncology · 2021 · 428 citations · Full text

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 330 citations

Medicine, Thyroid Disease, Pathology +8